

5

FORMULATION OF AN ERODIBLE, GASTRIC RETENTIVE  
ORAL DOSAGE FORM USING IN VITRO DISINTEGRATION TEST DATA

10       Erodible, gastric-retentive dosage forms are provided that are formulated using the  
in *vitro* drug release profile obtained with USP Disintegration test equipment rather the  
USP Dissolution Apparatus. The invention is premised on the discovery that the USP  
Disintegration Test and modified versions thereof are far more predictive of the *in vivo*  
release profile for a controlled release dosage form than is the standard USP Dissolution  
15      Test, particularly controlled release dosage forms of the swellable, erodible type. The  
dosage forms generally comprise particles of a biocompatible, hydrophilic polymer having  
the active agent incorporated therein, wherein the particles are optionally but preferably  
compacted into a tablet or loaded into a capsule. The dosage forms can be used to deliver  
water-insoluble or sparingly soluble drugs as well as water-soluble drugs, providing that  
20      the latter are coated with a protective coating or contained in a protective vesicle.